2.08
-0.01(-0.48%)
Currency In USD
| Previous Close | 2.09 |
| Open | 2.09 |
| Day High | 2.13 |
| Day Low | 2.07 |
| 52-Week High | 3.2 |
| 52-Week Low | 1.26 |
| Volume | 106,493 |
| Average Volume | 213,124 |
| Market Cap | 59.92M |
| PE | -2.7 |
| EPS | -0.77 |
| Moving Average 50 Days | 2.31 |
| Moving Average 200 Days | 2.11 |
| Change | -0.01 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $566.76 as of October 02, 2025 at a share price of $2.08. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $1,496.4 as of October 02, 2025 at a share price of $2.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Yesterday at 12:45 PM GMT
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today anno
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
GlobeNewswire Inc.
Sep 18, 2025 5:30 PM GMT
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
GlobeNewswire Inc.
Sep 11, 2025 1:15 PM GMT
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopha